Today: 3 June 2026
Browse Category

Pharmaceuticals 8 February 2026 - 10 February 2026

Merck stock price slips after insider sale filings; what MRK investors are watching next

Merck stock price slips after insider sale filings; what MRK investors are watching next

Merck shares fell 0.5% to $117.01 after SEC filings showed insider stock sales by two executives on Feb. 9. Chief Marketing Officer Chirfi Guindo sold 10,000 shares; Executive Vice President Jennifer Zachary exercised and sold 121,573 shares. The moves followed a revenue forecast below Wall Street estimates. Merck underperformed the broader market and sector peers.
10 February 2026
··
Hims & Hers stock price slides again as Novo Nordisk lawsuit tightens the screws on Wegovy copies

Hims & Hers stock price slides again as Novo Nordisk lawsuit tightens the screws on Wegovy copies

Hims & Hers Health shares fell 5.6% to $18.25 Tuesday after Novo Nordisk filed a U.S. patent lawsuit seeking to block sales of compounded versions of its Wegovy weight-loss drug. The FDA has said semaglutide is no longer in shortage, tightening rules on compounding. Hims pulled its $49 compounded semaglutide pill days after launch. Investors await Hims’ earnings on Feb. 23.
10 February 2026
···
Eli Lilly stock price dips as $2.4 billion Orna deal and China pact grab attention

Eli Lilly stock price dips as $2.4 billion Orna deal and China pact grab attention

Eli Lilly shares fell 0.9% to $1,035.54 Tuesday morning after new deals in cell therapy and China drug development. The company agreed to buy Orna Therapeutics for up to $2.4 billion and struck a collaboration with Innovent Biologics. Investors weighed increased pipeline spending as competition in obesity drugs intensified. Attention turns to an upcoming FDA decision on Lilly’s oral obesity pill.
10 February 2026
··
Hims & Hers stock drops again premarket as $49 weight-loss pill reversal fuels legal, FDA scrutiny

Hims & Hers stock drops again premarket as $49 weight-loss pill reversal fuels legal, FDA scrutiny

Hims & Hers Health shares dropped 4.2% to $18.52 premarket Tuesday after plunging 16% Monday. The company halted its compounded semaglutide pill following warnings from U.S. regulators and a new patent lawsuit by Novo Nordisk. The FDA signaled plans to restrict non-approved GLP-1 drugs and may take legal action. The Department of Health and Human Services referred Hims to the Justice Department.
10 February 2026
···
CSL shares slide as CEO Paul McKenzie retires, Gordon Naylor named interim ahead of results

CSL shares slide as CEO Paul McKenzie retires, Gordon Naylor named interim ahead of results

CSL said CEO Paul McKenzie will retire, appointing Gordon Naylor as interim chief from Feb. 11. Shares closed down 4.98% after the announcement, which came after market close. Naylor, a former Seqirus and finance head, will lead Wednesday’s half-year results briefing. The leadership change follows weak U.S. flu vaccine demand and delayed plans to spin off Seqirus.
10 February 2026
··
Hims & Hers stock sinks after $49 Wegovy copycat U-turn and Novo Nordisk lawsuit

Hims & Hers stock sinks after $49 Wegovy copycat U-turn and Novo Nordisk lawsuit

Hims & Hers Health shares plunged 16% in after-hours trading Monday after the company pulled its $49 compounded semaglutide pill amid a patent lawsuit from Novo Nordisk. The stock touched $16.44 before recovering some losses. Novo seeks a court order to stop sales of unapproved compounded drugs. Leerink Partners cut its price target on Hims, citing uncertainty over future sales of compounded semaglutide.
10 February 2026
···
Arrowhead Pharmaceuticals stock swings as S&P MidCap 400 move lands and Goldman flags 2026 catalysts (ARWR)

Arrowhead Pharmaceuticals stock swings as S&P MidCap 400 move lands and Goldman flags 2026 catalysts (ARWR)

Arrowhead Pharmaceuticals shares fell 0.7% to $64.10 in afternoon trading Monday after moving from the S&P SmallCap 600 to the S&P MidCap 400. The stock saw heavy volume and a wide intraday range. Goldman Sachs maintained a Neutral rating and $85 target, citing key 2026 pipeline data and competition from Ionis Pharmaceuticals. Arrowhead recently reported Q1 revenue of $264 million and 22 cents EPS.
9 February 2026
··
Merck stock drops nearly 4%: why MRK is lagging the market today

Merck stock drops nearly 4%: why MRK is lagging the market today

Merck shares fell 3.9% to $117.16 Monday, underperforming the broader market as investors weighed patent risks and 2026 earnings guidance. Amgen, Pfizer, and AbbVie also declined. Merck last week projected 2026 sales of up to $67 billion and warned of a $2.5 billion hit from generic competition and weaker COVID-19 drug sales. The Dow lagged as Merck and Amgen dragged on the index.
9 February 2026
··
Novo Nordisk stock jumps 8% as Hims drops $49 semaglutide pill plan

Novo Nordisk stock jumps 8% as Hims drops $49 semaglutide pill plan

Novo Nordisk shares jumped 8.3% in Copenhagen after Hims & Hers scrapped plans to sell a $49 compounded semaglutide weight-loss pill. The move follows U.S. regulatory warnings and legal threats over mass-marketed compounded GLP-1 drugs. The FDA signaled enforcement action against unapproved compounded versions. Eli Lilly plans to launch a competing weight-loss pill in April.
9 February 2026
····
Novo Nordisk Class B stock: what to watch after Hims pulls $49 Wegovy pill copy

Novo Nordisk Class B stock: what to watch after Hims pulls $49 Wegovy pill copy

Novo Nordisk B shares rose 5.29% to 295.50 Danish crowns Friday after Hims & Hers said it would stop selling a $49 compounded version of Novo’s Wegovy pill. The rebound followed a steep two-day drop and came as the FDA pledged action against mass-marketed copycats. The stock remains down about 20% over five sessions. Investors remain uncertain about Novo’s patent protections and future pricing power.
8 February 2026
···
Novartis share price sits near a 52-week high after San Diego research build — what investors watch next

Novartis share price sits near a 52-week high after San Diego research build — what investors watch next

Novartis shares closed up 0.57% at CHF 119.96 in Zurich on Friday, hitting a 52-week high of CHF 120.64. The company broke ground on a 466,000-square-foot research center in San Diego, set to open in 2029. Investors await the March 6 shareholder meeting and March 10 ex-dividend date. Novartis forecasts a low single-digit decline in 2026 adjusted operating profit due to patent expiries.
8 February 2026
··
Healthcare stocks set up for Monday: Hims drops $49 Wegovy copycat as FDA targets compounded GLP-1s

Healthcare stocks set up for Monday: Hims drops $49 Wegovy copycat as FDA targets compounded GLP-1s

Hims & Hers will stop offering a compounded semaglutide pill after the FDA signaled a crackdown on copycat GLP-1 drugs. Hims shares fell 15.9% to $19.36 on Friday. Molina Healthcare plunged over 28% after forecasting 2026 profit far below expectations and announcing an exit from Medicare Advantage prescription drug plans. The Health Care Select Sector SPDR Fund closed up 1.85% at $157.71.
8 February 2026
··
Merck stock is inches from a 52-week high — and an insider just sold shares

Merck stock is inches from a 52-week high — and an insider just sold shares

Merck shares closed up 1.8% at $121.93 on Friday, marking a seventh straight gain and finishing just below a 52-week high. A regulatory filing showed Animal Health chief Richard R. DeLuca sold 37,685 shares on Feb. 6 at an average of $120.92. Trading volume was about 13 million shares, below the 50-day average. Investors await Monday trading after Merck’s 2026 outlook and pipeline updates.
8 February 2026
··
Roche share price set for Monday test after MS drug fenebrutinib data lands

Roche share price set for Monday test after MS drug fenebrutinib data lands

Roche said its experimental MS drug fenebrutinib met the main goal in a late-stage study for primary progressive multiple sclerosis, showing “non-inferiority” to Ocrevus but with more frequent, reversible liver enzyme elevations and a higher share of fatal cases. Roche shares last closed down 0.6% at 356.40 francs. Investors await Monday’s webcast for more data and filing plans.
8 February 2026
····
1 … 4 5 6 7 8 … 41

Latest articles

INFQ back on radar after UK quantum push; shares jump

INFQ back on radar after UK quantum push; shares jump

3 June 2026
Infleqtion shares surged 12.4% to $19.87 in late New York trading after announcing Gold Sponsorship of Quantum Fringe 2026 and new U.K. quantum partnerships, as investors bet on government contracts and expanded manufacturing, despite a $30.3 million quarterly net loss and warnings of ongoing operating losses if public-sector funding slows.
Corning shares move after AI news

Corning shares move after AI news

3 June 2026
Corning soared 13.4% to $200.40 on heavy volume after Nvidia’s CEO spotlighted the need for optical links in AI data centers, with Corning’s recent Nvidia and Meta deals making it a top play on AI infrastructure; first-quarter core sales jumped 18% and optical sales surged 36%, but investors face risks from consumer electronics demand and execution on new factory expansions.
Quantum computing stocks face a holiday week after IonQ stake filing and a Rigetti downgrade

IonQ Stock Jumped Again. A Giant Quantum IPO Is Putting the Trade on Trial

3 June 2026
IonQ shares closed up 3.1% at $71.40 before slipping 1.3% after hours as traders positioned ahead of Quantinuum’s upsized IPO, which seeks up to $1.46 billion at a $14.3 billion valuation; IonQ’s Q1 revenue surged 755% to $64.7 million with a raised 2026 outlook, but a $271.5 million operating loss and guidance for continued high expenses highlight risks as Wall Street awaits new sector benchmarks.
Xos Surges After Hours as Data-Center Power Play Hits Tape

Xos Surges After Hours as Data-Center Power Play Hits Tape

3 June 2026
Xos shares soared 135.8% to $5.26 in after-hours trading after launching a 2.5MWh Power Hub for data centers facing grid delays, but the company warned of "substantial doubt" about its ability to continue as a going concern, with just $9.8 million in cash at March 31 and no large orders yet announced for the new product.
Social Security checks may see biggest increase in years, but there’s a catch

Social Security checks may see biggest increase in years, but there’s a catch

3 June 2026
Early forecasts show the 2027 Social Security cost-of-living adjustment could hit 4%, driven by surging gasoline and energy prices, marking the largest benefit increase since 2023 for 71.1 million recipients; the final figure, set in October, depends on third-quarter inflation data, with falling fuel prices or easing supply risks posing downside risks to the estimate.
Go toTop